Abbott Receives CE Mark for Dual Glucose-Ketone Sensor

Why It Matters

Continuous ketone monitoring could reduce DKA‑related hospitalizations and enable tighter, automated insulin therapy, reshaping diabetes care standards.

Key Takeaways

• Abbott's Libre Duo gets CE mark, first EU dual glucose‑ketone sensor.
• 15‑day adult version and 10‑day pediatric version launch in Europe 2026.
• Continuous ketone monitoring may cut diabetic ketoacidosis hospitalizations.
• FDA decision expected H2 2026, paving way for US market entry.
• Dexcom lags, targeting glucose‑potassium sensors instead of ketones.

Pulse Analysis

Abbott’s Libre Duo marks a watershed moment in diabetes technology by pairing continuous glucose monitoring with real‑time ketone detection. Until now, patients have relied on intermittent finger‑stick tests or urine strips to gauge ketone levels, a process that can miss the early rise of diabetic ketoacidosis (DKA). The CE‑marked device offers a 15‑day wear sensor for adults and a 10‑day version for children as young as two, delivering two streams of data on a single transmitter. This consolidation simplifies daily routines and positions Abbott at the forefront of multi‑analyte wearables.

The clinical upside is substantial. DKA accounts for a disproportionate share of diabetes‑related hospital admissions, and early detection can dramatically reduce morbidity and cost. By alerting users to rising ketones before symptoms become severe, Libre Duo enables timely medical intervention, potentially curbing the four‑fold higher hospitalization rate for hyperglycemic crises reported in 2021. Moreover, Abbott’s partnership talks with insulin‑pump manufacturers hint at future closed‑loop systems that automatically adjust insulin delivery based on both glucose and ketone trends, a capability that could redefine tight‑glycemic control.

From a market perspective, Abbott’s clearance gives it a first‑mover advantage in Europe while rivals scramble to catch up. Dexcom, for instance, has signaled interest in dual‑sensor platforms but is prioritizing glucose‑potassium combos aimed at chronic kidney disease patients, leaving ketone monitoring to Abbott for now. The device is also under FDA review, with a projected approval window in the second half of 2026, which would unlock the sizable U.S. market. As continuous monitoring expands beyond glucose, the dual‑analyte model may become the new benchmark for diabetes care.